MARKETS
Markets

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".

Sep 2, 2026 · 03:59 PM ET· updated 55m ago

https://patentcenter.uspto.gov/applications/18255342/ifw/docs

Share
Why It Matters

Aptevo got official approval from the U.S. government to own a patent—a special permission that only they can use an invention. This shows their science is real, and it's harder for other companies to copy their cancer-fighting idea.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.